source
- Phase 3 trial shows cancer vaccine intismeran autogene cuts recurrence risk by 42% versus KeytrudaAt the European Society for Medical Oncology Congress, a Phase 3 trial of the personalized cancer vaccine intismeran autogene reported a 42% reduction in risk of recurrence or death compared with p…
- Novartis reaffirms $12 billion Avidity acquisition despite $1.9 billion impairment lossNovartis said its $12 billion purchase of Avidity Biosciences remains on track, according to CEO Vas Narasimhan. The comment followed the company's disclosure of a $1.9 billion impairment charge t…